Insmed Inc (INSM) Peer Comparison
$118.46
$-2.93
(-2.41%)
As on 28-Aug-2026 13:38EDT
Market cap
$27,466 Mln
Revenue (TTM)
$1,138 Mln
P/E Ratio
--
P/B Ratio
36.3
Div. Yield
0 %
Edit
| Insmed Inc (INSM) | Vertex Pharmaceuticals (VRTX) | Regeneron Pharmaceuticals (REGN) | Moderna (MRNA) | Revolution Medicines (RVMD) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
27,466 | 138,909 | 85,869 | 57,941 | 44,895 |
Revenue ($ Mln) |
1,138 | 12,624 | 15,535 | 2,228 | -- |
Net Profit ($ Mln) |
-875.31 | 4,405.20 | 4,328.70 | -3,151.00 | -1,768.29 |
Net Margin (%) |
-76.94 | 34.89 | 27.86 | -141.43 | -- |
RoE (%) |
-116.98 | 22.64 | 13.75 | -40.89 | -83.46 |
Price to Earnings |
-- | 31.44 | 20.45 | -- | -- |
Price-To-Book |
36.26 | 6.76 | 2.68 | 8.57 | 17.41 |
Income Statement ($ Mln)
| Insmed Inc (INSM) | Vertex Pharmaceuticals (VRTX) | Regeneron Pharmaceuticals (REGN) | Moderna (MRNA) | Revolution Medicines (RVMD) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
1,137.64 | 12,624.30 | 15,534.70 | 2,228.00 | 0.00 |
|
Cost of Revenue
|
190.30 | 1,762.80 | 2,352.10 | 2,508.00 | 9.24 |
|
Gross Profit
|
481.55 | 10,267.50 | 12,242.20 | 1,076.00 | -16.56 |
|
Operating Expenses
|
1,764.88 | 5,989.90 | 9,212.50 | 3,040.00 | 1,618.01 |
|
Operating Profit (EBIT)
|
-817.54 | 4,872.00 | 3,970.10 | -3,320.00 | -1,627.25 |
|
Other Income
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Profit before Tax
|
-869.11 | 5,274.90 | 5,166.00 | -3,087.00 | -1,768.29 |
|
Provision for Tax
|
6.21 | 869.30 | 837.30 | 64.00 | 0.00 |
|
Profit after Tax (Net Income)
|
-875.31 | 4,405.20 | 4,328.70 | -3,151.00 | -1,768.29 |
|
Minority Interest
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Consolidated Profit
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Liabilities ($ Mln)
| Insmed Inc (INSM) | Vertex Pharmaceuticals (VRTX) | Regeneron Pharmaceuticals (REGN) | Moderna (MRNA) | Revolution Medicines (RVMD) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
757.49 | 20,247.90 | 31,711.00 | 6,761.00 | 2,606.24 |
|
Minority Interest
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Non-Current Liabilities
|
906.33 | 3,237.50 | 4,488.60 | 1,666.00 | 1,362.97 |
|
Current Liabilities
|
438.74 | 3,937.90 | 5,530.60 | 2,534.00 | 354.06 |
|
Total Liabilities
|
2,264.56 | 26,142.80 | 40,558.70 | 12,338.00 | 2,354.51 |
Assets ($ Mln)
| Insmed Inc (INSM) | Vertex Pharmaceuticals (VRTX) | Regeneron Pharmaceuticals (REGN) | Moderna (MRNA) | Revolution Medicines (RVMD) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
468.65 | 14,879.60 | 23,284.00 | 5,146.00 | 294.93 |
|
Current Assets
|
1,633.92 | 12,543.70 | 18,446.00 | 5,815.00 | 4,028.34 |
|
Total Assets
|
2,264.56 | 26,142.80 | 40,558.70 | 12,338.00 | 2,354.51 |
|
Total Debt*
|
579.88 | 1,977.60 | 1,986.60 | 1,287.00 | 641.93 |
|
Net Current Assets
|
1,195.18 | 8,605.80 | 12,915.40 | 3,281.00 | 3,674.28 |
Cashflow ($ Mln)
| Insmed Inc (INSM) | Vertex Pharmaceuticals (VRTX) | Regeneron Pharmaceuticals (REGN) | Moderna (MRNA) | Revolution Medicines (RVMD) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-935.01 | 3,631.40 | 4,978.90 | -1,873.00 | -897.74 |
|
Cash Flow from Investing Activities
|
-64.58 | -945.40 | -629.10 | 1,946.00 | 118.06 |
|
Cash from Financing Activities
|
954.07 | -2,261.30 | -3,715.40 | 593.00 | 621.52 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Insmed Inc (INSM) | Vertex Pharmaceuticals (VRTX) | Regeneron Pharmaceuticals (REGN) | Moderna (MRNA) | Revolution Medicines (RVMD) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-82.20 | 19.42 | 13.65 | -25.41 | -53.99 |
|
ROE (%)
|
-116.98 | 22.64 | 13.75 | -40.89 | -83.46 |
|
ROA (%)
|
-32.83 | 14.80 | 9.71 | -23.27 | -48.50 |
|
EBIT Margin (%)
|
-69.49 | 41.83 | 33.61 | -137.79 | -- |
|
Net Margin (%)
|
-76.94 | 34.89 | 27.86 | -141.43 | -- |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | -- |
Growth Ratios
| Insmed Inc (INSM) | Vertex Pharmaceuticals (VRTX) | Regeneron Pharmaceuticals (REGN) | Moderna (MRNA) | Revolution Medicines (RVMD) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
185.76 | 10.56 | 9.29 | -27.19 | -- |
|
EBIT Growth (%)
|
16.83 | 20.31 | 6.31 | -4.74 | -33.90 |
|
Net Profit Growth (%)
|
15.38 | 21.10 | -2.91 | -8.54 | -117.75 |
|
EPS Growth (%)
|
27.98 | 22.80 | 1.72 | -6.34 | -95.21 |
|
Book Value Growth (%)
|
-47.21 | 19.36 | 7.70 | -29.52 | 24.65 |
Valuation Ratios
| Insmed Inc (INSM) | Vertex Pharmaceuticals (VRTX) | Regeneron Pharmaceuticals (REGN) | Moderna (MRNA) | Revolution Medicines (RVMD) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-29.12 | 29.37 | 18.42 | -4.10 | -13.39 |
|
Price / Book Value
|
50.31 | 6.22 | 2.65 | 1.34 | 9.28 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
-31.17 | 23.31 | 13.25 | -3.01 | -12.17 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Insmed Inc (INSM) | Vertex Pharmaceuticals (VRTX) | Regeneron Pharmaceuticals (REGN) | Moderna (MRNA) | Revolution Medicines (RVMD) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.72 | 0.00 | 0.06 | 0.09 | 0.19 |
|
Short term debt to equity ratio
|
0.01 | 0.00 | 0.00 | 0.01 | 0.01 |
|
Current Ratio
|
3.72 | 3.19 | 3.34 | 2.29 | 11.38 |
|
Quick Ratio
|
3.40 | 2.74 | 2.78 | 2.18 | 11.38 |
|
Interest Coverage
|
-9.69 | 800.23 | 94.25 | -72.50 | -28.80 |
Operating Efficiency Ratios
| Insmed Inc (INSM) | Vertex Pharmaceuticals (VRTX) | Regeneron Pharmaceuticals (REGN) | Moderna (MRNA) | Revolution Medicines (RVMD) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
18.93 | 16.91 | 42.26 | 4.62 | -- |
|
Asset Turnover
|
0.43 | 0.42 | 0.35 | 0.16 | 0.00 |
|
Receivable days
|
58.08 | 55.39 | 152.19 | 82.29 | -- |
|
Inventory Days
|
337.31 | 292.28 | 546.66 | 56.81 | -- |
|
Payable days
|
223.67 | 88.40 | 150.27 | 151.91 | 1,312.97 |
|
Cash Conversion Cycle
|
171.72 | 259.28 | 548.59 | -12.81 | -- |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
